

**JOINT COMMITTEE ON FINANCIAL SERVICES
2025-2026 (194th) BILL SUMMARY**

Bill No: H1300

Title: AN ACT RELATIVE TO CANNABIS FOR MEDICARE ELIGIBLE PATIENTS

Sponsor: Rep. David M. Rogers (*Cambridge*)

Hearing Date: October 14, 2025

Reporting Deadline: December 3, 2025

Prior History: None

Similar Matters: SD2686 (Crighton – Identical, in House Rules); H1241 (LeBoeuf)

CURRENT LAW:

M.G.L. c. 32A Contributory Group General or Blanket Insurance for Persons in the Service of the Commonwealth (Group Insurance Commission)

M.G.L. c. 94I: Medical Use of Marijuana § 1 Definitions

This section defines “Electronic certification” as a document signed or executed electronically by a registered healthcare professional, stating that in the healthcare professional's professional opinion, the potential benefits of the medical use of marijuana would likely outweigh the health risks for the qualifying patient. Such certification will be made only during a bona fide healthcare professional-patient relationship and will specify the qualifying patient's debilitating medical condition. Electronic certifications, upon submission by a healthcare professional to the Massachusetts Cannabis Control Commission, will automatically generate a temporary registration.

This section defines “Healthcare professional” as a duly Massachusetts licensed physician, physician assistant or certified nurse practitioner authorized by the commission to issue written certifications.

M.G.L. c. 175 Insurance

M.G.L. c. 176A Non-Profit Hospital Service Corporations (Blue Cross of Massachusetts)

M.G.L. c. 176B Medical Service Corporations (Blue Shield of Massachusetts)

M.G.L. c. 176G Health Maintenance Organizations (HMOs)

SUMMARY:

SECTION 1. This bill would make health care providers certifying a patient, over 65 years of age, for the use of medical marijuana, eligible for reimbursement for such certification by the Group Insurance Commission and commercial health insurers.

SECTION 2. This bill would allow health plans to include cannabis for medical use, in their formulary, subject to inclusion on Schedule II, Schedule III, Schedule IV, Schedule V, or Schedule VI under the Department of Public Health's Drug Control Program.